Price (90d)
$54.85Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.09B | $190.30M | $3.93 |
| 2025 | $1.14B | $214.60M | $4.32 |
| 2024 | $1.13B | $209.34M | $4.21 |
| 2023 | $1.13B | $-82.31M | $-1.65 |
| 2022 | $1.09B | $205.38M | $4.09 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $1.06 per share
Typical surprise +1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.98 vs $0.89beat
- Wed, May 13$1.23 vs $1.39miss
- Thu, Feb 5$1.14 vs $1.16miss
- Thu, Nov 6$1.07 vs $0.97beat
- Thu, Aug 7$0.95 vs $1.01miss
- Thu, May 8$1.32 vs $1.30beat
Estimates and results for PBH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PBH's reported EPS growth of -1.0% a year over 4 years.
- EPS in 5 years
- $3.73
- Implied price
- $56.02
- Return from $51.38
- 1.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $27.85 — -45.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -11.0% | -14.0% | -11.1% | -8.5% | -6.2% | -4.1% |
| -6.0% | -9.2% | -6.1% | -3.4% | -0.9% | 1.3% |
| -1.0% | -4.4% | -1.1% | 1.7% | 4.3% | 6.7% |
| 4.0% | 0.5% | 3.9% | 6.9% | 9.6% | 12.1% |
| 9.0% | 5.3% | 8.9% | 12.0% | 14.9% | 17.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (3)
- Newszacks.com·3d ago·Negative
PBH or SYK: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsmarketbeat.com·5d ago·Positive
Premium Brands Q2 Earnings Call Highlights Premium Brands TSE: PBH said its revised 2026 outlook reflects timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in the company's underlying operating assumptions.
View source ↗ - Newsmarketbeat.com·6d ago·Positive
Prestige Consumer Healthcare Q1 Earnings Call Highlights Prestige Consumer Healthcare NYSE: PBH reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.
View source ↗